CompletedPhase 2NCT00476853
Efficacy Safety Study Comparing 2 Doses of NVP After Initiating Rifampin-containing TB Therapy
Studying Primary genito-urinary tuberculosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
- Principal Investigator
- Anchalee Avihingsanon, MD, M.DThe HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)
- Intervention
- HAART containing nevirapine(drug)
- Enrollment
- 42 target
- Eligibility
- 18-60 years · All sexes
- Timeline
- 2005 – 2009
Study locations (6)
- The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand
- Chiangrai Hospital, Chiang Rai, Thailand
- Mae Chan Hospital, Chiang Rai, Thailand
- Phan Hospital, Chiang Rai, Thailand
- Bamrasnaradura Institute, Nonthaburi, Thailand
- Central Chest Hospital, Nonthaburi, Thailand
Collaborators
other sponsors:Japanese MOPH · Labor and Welfare · Thai MOPH · Thai GPO · Bamrasnaradura Infectious Diseases Institute · Chiang Rai Hospital · King Chulalongkorn Memorial Hospital · Central General Chest Institute · The Research Institute of Tuberculosis (Japan)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00476853 on ClinicalTrials.govOther trials for Primary genito-urinary tuberculosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05917210Peer-led Implementation of TB-HIV Education and Adherence Counseling in UgandaYale University
- RECRUITINGNCT07312266Questioning the Epidemiology of Asymptomatic TBBarcelona Institute for Global Health
- RECRUITINGNANCT05842161South Africa Smoking Cessation and Engagement in HIV/TB Care CareMassachusetts General Hospital
- RECRUITINGPHASE3NCT05575518A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary TuberculosisStellah Mpagama
- ACTIVE NOT RECRUITINGPHASE4NCT05118490Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis PatientsThe Aurum Institute NPC
- RECRUITINGNANCT05342064Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered ServiceBaylor College of Medicine